Bedrijfstakpensioenfonds Voor De Media Pno increased Electronic Arts Inc (EA) stake by 180% reported in 2018Q4 SEC filing. Bedrijfstakpensioenfonds Voor De Media Pno acquired 45,000 shares as Electronic Arts Inc (EA)’s stock rose 13.26%. The Bedrijfstakpensioenfonds Voor De Media Pno holds 70,000 shares with $5.52M value, up from 25,000 last quarter. Electronic Arts Inc now has $29.47 billion valuation. The stock decreased 1.01% or $1 during the last trading session, reaching $98.36. About 6.54M shares traded. Electronic Arts Inc. (NASDAQ:EA) has declined 20.37% since March 10, 2018 and is downtrending. It has underperformed by 24.74% the S&P500. Some Historical EA News: 07/03/2018 – EA and Maxis lnvite Players to Play with Life in The Sims Mobile, Available Worldwide Today; 20/03/2018 – S&P REVISES ELECTRONIC ARTS INC. TO RATING ‘BBB+’ FROM ‘BBB’; 12/04/2018 – ELECTRONIC ARTS NAMES PATRICK SODERLUND CHIEF DESIGN OFFICER; 23/05/2018 – ELECTRONIC ARTS MAY BE RAISED BY MOODY’S; 20/03/2018 – S&PGR Upgrades Electronic Arts Inc. To ‘BBB+’; Outlook Stable; 12/04/2018 – ELECTRONIC ARTS INC SAYS LAURA MIELE WILL BECOME CO’S CHIEF STUDIOS OFFICER; 08/05/2018 – Electronic Arts 4Q EPS $1.95; 08/05/2018 – Electronic Arts Sees FY19 Net Bookings About $5.55B; 23/05/2018 – MOODY’S PLACES ELECTRONIC ARTS, INC.’S Baa2 SR UNSECURED; 15/05/2018 – EMINENCE BOOSTED LEN, PZZA, EA, MGM, LQ IN 1Q: 13F

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had an increase of 1.32% in short interest. DRNA’s SI was 5.65 million shares in March as released by FINRA. Its up 1.32% from 5.58 million shares previously. With 297,200 avg volume, 19 days are for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The stock decreased 1.53% or $0.17 during the last trading session, reaching $10.93. About 1.01M shares traded or 74.43% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has 0.00% since March 10, 2018 and is . It has underperformed by 4.37% the S&P500. Some Historical DRNA News: 14/05/2018 – Dicerna Pharmaceuticals Believes It Has Sufficient Cash Through 2019, Assuming No New Fundin; 20/04/2018 – DICERNA PHARMACEUTICALS INC – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 08/03/2018 – DICERNA SEES SUFFICIENT CASH TO FUND DEVELOPMENT THRU 2019; 20/04/2018 – DICERNA PHARMACEUTICALS INC – DICERNA WILL DISMISS ALL COUNTERCLAIMS ASSOCIATED WITH ALNYLAM’S TRADE SECRET MISAPPROPRIATION LITIGATION; 20/04/2018 – ADVISORY-Alert on Dicerna, Alnylam litigation settlement wrongly coded to American Lorain; 20/04/2018 – DICERNA PHARMACEUTICALS – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 30/05/2018 – DICERNA PHARMACEUTICALS INC – EXPECTS TO HAVE CLINICAL PROOF-OF-CONCEPT DATA FROM PHYOX TRIAL IN SECOND HALF OF 2018; 20/04/2018 – DICERNA REPORTS SETTLEMENT OF ALL LITIGATION WITH ALNYLAM; 08/03/2018 Dicerna Pharmaceuticals 4Q Loss/Shr 90c; 08/03/2018 – DICERNA PHARMACEUTICALS – BELIEVES IT HAS SUFFICIENT CASH TO FUND EXECUTION OF CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019

More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Businesswire.com which released: “Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) – Business Wire” on March 01, 2019, also Globenewswire.com with their article: “New Research: Key Drivers of Growth for Energy Transfer LP, Domo, Accenture, Chevron, Cincinnati Financial, and Dicerna Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” published on March 06, 2019, Prnewswire.com published: “Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer – PRNewswire” on February 12, 2019. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Seekingalpha.com and their article: “Dicerna shakes up board – Seeking Alpha” published on January 24, 2019 as well as Seekingalpha.com‘s news article titled: “Alexion’s Complementary Growth Strategy – Seeking Alpha” with publication date: February 14, 2019.

Among 3 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Dicerna Pharmaceuticals had 7 analyst reports since September 13, 2018 according to SRatingsIntel. FBR Capital upgraded Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Tuesday, November 6 to “Buy” rating. The rating was maintained by Citigroup on Tuesday, October 30 with “Buy”. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Neutral” rating by FBR Capital on Monday, September 17.

Investors sentiment increased to 3.24 in Q4 2018. Its up 0.99, from 2.25 in 2018Q3. It is positive, as 10 investors sold Dicerna Pharmaceuticals, Inc. shares while 11 reduced holdings. 26 funds opened positions while 42 raised stakes. 95.22 million shares or 115.10% more from 44.27 million shares in 2018Q3 were reported. Artal Gru Sa holds 0.21% or 525,000 shares in its portfolio. Price T Rowe Associate Md holds 0% or 332,615 shares in its portfolio. Jpmorgan Chase & Co holds 0% or 13,738 shares in its portfolio. Birchview Cap L P has invested 0.46% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Voya Invest Mgmt Limited Liability Co invested in 0% or 22,263 shares. Adage Capital Prns Gru Ltd Limited Liability Company holds 0.09% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 3.05 million shares. Invesco, Georgia-based fund reported 141,438 shares. Dekabank Deutsche Girozentrale invested in 23,000 shares. Manufacturers Life Insurance The owns 31,503 shares. Eam Llc invested in 35,673 shares or 0.1% of the stock. Pennsylvania-based Vanguard has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Blackrock Inc has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bancorp Of Mellon Corp accumulated 0% or 218,093 shares. Sio Cap Mgmt Lc owns 443,409 shares for 1.73% of their portfolio. 600 were reported by Numerixs Invest Techs Incorporated.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $685.66 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Since October 30, 2018, it had 0 insider buys, and 2 sales for $12.17 million activity. $7.71 million worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was sold by Halak Brian K.

Since September 20, 2018, it had 0 buys, and 21 insider sales for $12.35 million activity. Singh Vijayanthimala had sold 200 shares worth $18,200 on Thursday, November 1. $105,491 worth of Electronic Arts Inc. (NASDAQ:EA) shares were sold by Miele Laura. Jorgensen Blake J sold $974,270 worth of stock or 10,500 shares. Soderlund Patrick sold $587,928 worth of stock or 5,000 shares. Another trade for 9,000 shares valued at $759,241 was sold by Wilson Andrew. 12,000 shares were sold by Bruzzo Chris, worth $1.23M. 1,000 shares valued at $102,810 were sold by Schatz Jacob J. on Monday, October 22.

Among 19 analysts covering Electronic Arts (NASDAQ:EA), 13 have Buy rating, 0 Sell and 6 Hold. Therefore 68% are positive. Electronic Arts had 23 analyst reports since September 11, 2018 according to SRatingsIntel. The rating was maintained by UBS on Thursday, February 28 with “Buy”. PiperJaffray maintained Electronic Arts Inc. (NASDAQ:EA) rating on Monday, December 10. PiperJaffray has “Overweight” rating and $105 target. As per Tuesday, February 19, the company rating was maintained by Bank of America. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, October 31. The stock of Electronic Arts Inc. (NASDAQ:EA) earned “Buy” rating by SunTrust on Thursday, March 7. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, February 13 report. Credit Suisse maintained it with “Outperform” rating and $126 target in Wednesday, October 31 report. The stock of Electronic Arts Inc. (NASDAQ:EA) earned “Outperform” rating by BMO Capital Markets on Friday, November 2. Robert W. Baird maintained Electronic Arts Inc. (NASDAQ:EA) rating on Monday, March 4. Robert W. Baird has “Buy” rating and $106 target. Stifel Nicolaus maintained the shares of EA in report on Tuesday, September 11 with “Buy” rating.

Bedrijfstakpensioenfonds Voor De Media Pno decreased Cl A stake by 2,000 shares to 28,000 valued at $29.26M in 2018Q4. It also reduced Booking Holdings Inc stake by 1,250 shares and now owns 8,350 shares. Union Pacific Corp (NYSE:UNP) was reduced too.

Investors sentiment decreased to 0.92 in 2018 Q4. Its down 0.33, from 1.25 in 2018Q3. It fall, as 91 investors sold EA shares while 217 reduced holdings. 92 funds opened positions while 190 raised stakes. 260.86 million shares or 3.75% less from 271.01 million shares in 2018Q3 were reported. Skytop Capital Mngmt Ltd holds 25,000 shares or 2.66% of its portfolio. Assetmark Inc accumulated 2,582 shares or 0% of the stock. Citadel Advisors Limited Liability accumulated 178,469 shares. Manufacturers Life Insurance The holds 0.05% in Electronic Arts Inc. (NASDAQ:EA) or 529,960 shares. Fukoku Mutual Life Insurance Com reported 0.02% of its portfolio in Electronic Arts Inc. (NASDAQ:EA). 1.60 million were reported by Alkeon Llc. 7,000 were reported by Gabelli Funds Llc. Trexquant Investment Lp accumulated 0.08% or 16,999 shares. Coastline Trust reported 16,185 shares stake. Fca Tx has 2,000 shares. Vision Mngmt invested in 31,915 shares or 0.79% of the stock. Csat Inv Advisory Ltd Partnership reported 130 shares. Fiduciary Tru Com stated it has 0.01% in Electronic Arts Inc. (NASDAQ:EA). Amer Registered Inv Advisor Inc stated it has 4,646 shares or 0.23% of all its holdings. 671,076 were reported by Natixis.